resTORbio Appoints William Marshall, M.D., as Vice President of Medical Sciences

BOSTON, Dec. 19, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq:TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of William Marshall, M.D., as Vice President of Medical Sciences at resTORbio.

“We are incredibly excited to have Bill join resTORbio as we continue to build out our team in anticipation of initiating our Phase 3 program to reduce the incidence of respiratory tract infections in high-risk elderly and our Phase 2 program in Parkinson’s disease,” said Chen Schor, Co-Founder, President and CEO of resTORbio. “Bill’s broad biopharma experience, spanning clinical pharmacology, the development and execution of late-stage clinical trials, and research in immunology and infectious disease, will be a great asset to our team.”

Dr. Marshall brings to resTORbio extensive clinical and R&D experience in infectious disease and neurology. He most recently was a Senior Director of Global Medical Sciences at Alexion, where he oversaw two Phase 3 programs in rare neurological indications. Before that, Dr. Marshall was a Principal Scientist and Clinical Director in Translational Therapeutics and Clinical Pharmacology at Merck. Prior to Merck, he served as a member of the Immune Tolerance Induction Review Board for Genzyme Corporation. Dr. Marshall is currently an Associate Professor of Medicine and on the Infectious Disease staff at University of Massachusetts Medical School and was previously an Instructor in Medicine at Harvard Medical School. He holds an M.D. from Columbia University Vagelos College of Physicians and Surgeons and a B.A. in Biology from Harvard University.

“Clinical and preclinical data to-date have demonstrated the broad potential of the TORC1 pathway to not only enhance immune function and lower the incidence of infections, but also ameliorate several other aging-related diseases,” said Dr. Marshall. “I look forward to our initiating the Phase 3 program in RTIs in the first half of 2019 and to being part of a dynamic team that is continuing to explore the potential of TORC1 inhibition for additional indications.”  

About resTORbio

resTORbio, Inc. is a clinical stage biopharmaceutical company targeting TORC1 and other biological pathways that regulate aging to develop innovative medicines with the potential to extend healthy lifespan. resTORbio’s lead program is selectively targeting TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiovascular and central nervous systems. Learn more about resTORbio, Inc. at

Forward Looking Statements:
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding our growth as a company and the anticipated contribution of our executives to our operations and progress, our plans to develop and commercialize RTB101 alone or in combination with everolimus or sirolimus, including the therapeutic potential and clinical benefits thereof and the potential patient populations that may be addressed by our product candidates, our ongoing and future clinical trials for RTB101 alone or in combination with everolimus or sirolimus, including the timing of the initiation and anticipated results of these trials, the planned expansion of our pipeline into Parkinson’s disease, the intended regulatory path for our product candidates and interactions with regulatory authorities, and our ability to replicate results achieved in our clinical trials in any future trials, constitute forward-looking statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the delay of any planned clinical trials and/or development of RTB101, either alone or in combination with everolimus or sirolimus; our ability to successfully demonstrate the efficacy and safety of our lead product candidate; the clinical results for our lead product candidate which may not support further development of additional indications; uncertainties related to the results of our clinical trials not being predictive of future results in connection with future trials; the timing and outcome of our planned interactions with regulatory authorities; and obtaining, maintaining and protecting our intellectual property; as well as those risks more fully discussed in the section entitled “Risk Factors” in the Annual Report on Form 10-K filed by resTORbio, Inc. with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing its views as of any subsequent date. resTORbio explicitly disclaims any obligation to update any forward-looking statements.

Investor Contact
Jennifer Robinson
resTORbio, Inc.

Media Contact
Christopher Hippolyte
Biosector 2


You May Also Like


賓夕法尼亞州普利茅斯會議, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc。(NASDAQ: INO)今日宣佈該公司最近發表的三項DNA編碼單克隆抗體(dMAb™)技術研究結果令人印象深刻。 在臨床前模擬試驗中治療心血管疾病和預防伊波拉病毒和萊姆病致病細菌的感染。利用最近公佈的幾項獲肯定的臨床前數據,Inovio計劃在明年初期獲得全面外部資金,開始研究dMAb產品對傳染病療效的首次臨床試驗。 傳統的單克隆抗體佔據當今醫藥市場中的最主要的部分,每年藥品銷售額超過500億美元,治療範圍從癌症和傳染病到炎症和心血管疾病。憑藉其合成設計和體內自行生產方法,Inovio的dMAb產品可為這一重要類別的藥物提供新穎、突破性的方法。當dMAb直接遞送到體內時,DNA質粒所提供的遺傳指令會使患者自身的細胞成為製造治療性抗體的工廠。 Inovio已獲得超過6,000萬美元的非稀釋性撥款資金,讓Inovio能在過去幾年推展其dMAb平台。最近,Bill ...